Digest Network Come funziona
Network
/
Società
In
Non verificato

Innoviva Specialty Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniIndustriaSalute

5 comunicati stampa

Guarda tutti i comunicati
11/08/2026
Eventi
Industria
HIV, AIDS e malattie autoimmuni
Biotecnologia
Farmaceutica
Salute
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Fonte
Innoviva Specialty Therapeutics
Emittente
Business Wire
1.00
0
16/06/2026
Mercato del lavoro
Biotecnologia
Igiene alimentare
Salute
Comunicazione
Farmaceutica
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
Fonte
Innoviva Specialty Therapeutics
Emittente
Business Wire
1.00
0
10/03/2026
Industria
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report
Fonte
Innoviva Specialty Therapeutics
Emittente
Business Wire
1.00
0
20/10/2025
Biotecnologia
Sanità
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Eventi
Fiere
Industria
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
Fonte
Innoviva Specialty Therapeutics
Emittente
Business Wire
1.00
0
07/10/2025
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Eventi
Industria
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
Fonte
Innoviva Specialty Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0